Pacira Pharmaceuticals Inc. is recalling 40,517 kits of Zilretta (triamcinolone acetonide extended-release injectable suspension), 32 mg per vial. The recall was initiated because the product failed dissolution testing, meaning the medication might not release at the correct rate into the body as intended. This specific lot of the prescription medication was distributed nationwide across the United States.
If the medication fails to meet dissolution specifications, it may not provide the expected long-term pain relief for patients or could potentially cause localized irritation at the injection site. No injuries or adverse health events have been reported to date.
Quarantine and return product.
Affected kit includes 5 mL sterile single-use vial of diluent.
If you or a family member were harmed by this recalled product, you may have legal rights. Consider consulting a consumer protection attorney to understand your options for compensation.
This is general information, not legal advice. Go Backs is not a law firm and does not provide legal services.
AI-Enhanced Content: The summary, action steps, and risk assessment on this page were generated by AI from official government recall data to improve readability. This is not legal or medical advice. Always refer to the official agency sources below for authoritative information.
Sources: FDA iRES · Raw API Response
openFDA Disclaimer: This recall information is sourced from the openFDA API. Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. Refer to the openFDA terms of service for more information.